Literature DB >> 10673992

Psychological factors can predict the response to primary chemotherapy in patients with locally advanced breast cancer.

L G Walker1, S D Heys, M B Walker, K Ogston, I D Miller, A W Hutcheon, T K Sarkar, A K Ah-See, O Eremin.   

Abstract

This study evaluated the possible value of psychological variables in predicting clinical and pathological response to primary chemotherapy. 96 women with newly diagnosed large, or locally advanced, breast cancer (T2 > 4 cm, T3, T4, N2 and M0) participated in a prospective, randomised trial to evaluate the effects of relaxation training with guided imagery and L-arginine on response to primary chemotherapy. Before the first of six cycles of primary chemotherapy, women were assessed using the Hospital Anxiety and Depression Scale (HADS) and the Eysenck Personality Questionnaire (EPQ). The primary outcomes were clinical response (evaluated using standard International Union Against Cancer (UICC) criteria) and pathological response (graded by means of a previously published 5-point scale) following primary chemotherapy. Stepwise linear regressions were used to estimate the predictive value of age, menopausal status, clinical nodal status, tumour size at diagnosis, oestrogen receptor status, dietary supplementation (L-arginine versus placebo), personality (EPQ-L scores), mood (HADS scores) and a psychological intervention. HADS depression score was a significant independent predictor of pathological response to chemotherapy. HADS anxiety score was a significant independent predictor of clinical response. Because the original tumour size before chemotherapy (also a significant predictor of clinical and pathological responses) was taken into account in the analyses, the results cannot be explained in terms of psychobiological factors related to tumour size. This study supports the importance of psychological factors as independent predictors of response to primary chemotherapy in patients with breast cancer. If they can be replicated, these findings have major implications for the management of women with breast cancer. Psychological factors need to be assessed and evaluated in future trials of chemotherapy.

Entities:  

Mesh:

Year:  1999        PMID: 10673992     DOI: 10.1016/s0959-8049(99)00169-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

1.  Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life.

Authors:  Hee J Yoo; Se H Ahn; Sung B Kim; Woo K Kim; Oh S Han
Journal:  Support Care Cancer       Date:  2005-04-23       Impact factor: 3.603

2.  Treatment-related symptoms among underserved women with breast cancer: the impact of physician-patient communication.

Authors:  Rose C Maly; Yihang Liu; Barbara Leake; Amardeep Thind; Allison L Diamant
Journal:  Breast Cancer Res Treat       Date:  2009-05-16       Impact factor: 4.872

3.  The value of the Hospital Anxiety and Depression Scale (HADS) for comparing women with early onset breast cancer with population-based reference women.

Authors:  R H Osborne; G R Elsworth; M A G Sprangers; F J Oort; J L Hopper
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

4.  An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with breast cancer.

Authors:  Jacqui Rodgers; Colin R Martin; Rachel C Morse; Kate Kendell; Mark Verrill
Journal:  Health Qual Life Outcomes       Date:  2005-07-14       Impact factor: 3.186

5.  Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.

Authors:  Jennifer Eremin; Ged Cowley; Leslie G Walker; Elisabeth Murray; Monika Stovickova; Oleg Eremin
Journal:  Springerplus       Date:  2015-01-13

6.  Predicting general and cancer-related distress in women with newly diagnosed breast cancer.

Authors:  Andrea Gibbons; AnnMarie Groarke; Karl Sweeney
Journal:  BMC Cancer       Date:  2016-12-03       Impact factor: 4.430

7.  Evaluating the factor structure, item analyses, and internal consistency of hospital anxiety and depression scale in Iranian infertile patients.

Authors:  Payam Amini; Saman Maroufizadeh; Reza Omani Samani
Journal:  Int J Reprod Biomed       Date:  2017-05

8.  Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial.

Authors:  A Barnadas; M Gil; S González; I Tusquets; M Muñoz; A Arcusa; L Prieto; M Margelí-Vila; A Moreno
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

Review 9.  Psychosocial interventions for patients with advanced cancer - a systematic review of the literature.

Authors:  R J Uitterhoeve; M Vernooy; M Litjens; K Potting; J Bensing; P De Mulder; T van Achterberg
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

10.  Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.

Authors:  B Brenner; N Siris; E Rakowsky; E Fenig; A Sulkes; H Lurie
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.